Genprex, Inc. - 8-K Filing
Genprex announced that the Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering Reqorsa® Gene Therapy in combination with PD-1 or PD-L1 antibodies for treating non-small cell lung cancer and small cell lung cancer. This expands prior patents granted in multiple countries, strengthening Genprex’s IP portfolio related to its ongoing Acclaim-3 clinical trial. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $GNPX